The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study

Kyra Y L Chua, Sara Vogrin, Susan Bury, Abby Douglas, Natasha E Holmes, Nixon Tan, Natasha K Brusco, Rebecca Hall, Belinda Lambros, Jacinta Lean, Wendy Stevenson, Misha Devchand, Kent Garrett, Karin Thursky, M Lindsay Grayson, Monica A Slavin, Elizabeth J Phillips, Jason A Trubiano, Kyra Y L Chua, Sara Vogrin, Susan Bury, Abby Douglas, Natasha E Holmes, Nixon Tan, Natasha K Brusco, Rebecca Hall, Belinda Lambros, Jacinta Lean, Wendy Stevenson, Misha Devchand, Kent Garrett, Karin Thursky, M Lindsay Grayson, Monica A Slavin, Elizabeth J Phillips, Jason A Trubiano

Abstract

Background: Penicillin allergies are associated with inferior patient and antimicrobial stewardship outcomes. We implemented a whole-of-hospital program to assess the efficacy of inpatient delabeling for low-risk penicillin allergies in hospitalized inpatients.

Methods: Patients ≥ 18 years of age with a low-risk penicillin allergy were offered a single-dose oral penicillin challenge or direct label removal based on history (direct delabeling). The primary endpoint was the proportion of patients delabeled. Key secondary endpoints were antibiotic utilization pre- (index admission) and post-delabeling (index admission and 90 days).

Results: Between 21 January 2019 and 31 August 2019, we assessed 1791 patients reporting 2315 antibiotic allergies, 1225 with a penicillin allergy. Three hundred fifty-five patients were delabeled: 161 by direct delabeling and 194 via oral penicillin challenge. Ninety-seven percent (194/200) of patients were negative upon oral penicillin challenge. In the delabeled patients, we observed an increase in narrow-spectrum penicillin usage (adjusted odds ratio [OR], 10.51 [95% confidence interval {CI}, 5.39-20.48]), improved appropriate antibiotic prescribing (adjusted OR, 2.13 [95% CI, 1.45-3.13]), and a reduction in restricted antibiotic usage (adjusted OR, 0.38 [95% CI, .27-.54]). In the propensity score analysis, there was an increase in narrow-spectrum penicillins (OR, 10.89 [95% CI, 5.09-23.31]) and β-lactam/β-lactamase inhibitors (OR, 6.68 [95% CI, 3.94-11.35]) and a reduction in restricted antibiotic use (OR, 0.52 [95% CI, .36-.74]) and inappropriate prescriptions (relative risk ratio, 0.43 [95% CI, .26-.72]) in the delabeled group compared with the group who retained their allergy label.

Conclusions: This health services program using a combination of direct delabeling and oral penicillin challenge resulted in significant impacts on the use of preferred antibiotics and appropriate prescribing.

Keywords: antibiotic allergy; antimicrobial stewardship; direct provocation; oral challenge; penicillin allergy.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Study profile. Positive oral challenge is defined as an immune or non-immune-mediated reaction following oral penicillin challenge. Negative oral challenge is defined as no reaction following oral penicillin challenge.
Figure 2.
Figure 2.
Antibiotic utilization in the delabeled cohort (n = 355). Errors bars represent 95% confidence intervals. aA narrow-spectrum penicillin was defined as 1 of penicillin VK, penicillin G, flucloxacillin, dicloxacillin, ampicillin, or amoxicillin. bAn unrestricted cephalosporin included first- or second-generation cephalosporins. cA restricted cephalosporin included third-generation or later cephalosporins. dA restricted antibiotic included lincosamides (ie, clindamycin, lincomycin), fluoroquinolones (ie, norfloxacin, ciprofloxacin, moxifloxacin), vancomycin, carbapenems (ie, ertapenem, meropenem), and third-generation or later cephalosporins (ie, cefepime, ceftazidime, ceftriaxone). Abbreviations: 90-day, 90-day posttesting admission; BL/BLI, β-lactam/β-lactamase inhibitor; pre, pretesting index admission; post, posttesting index admission.

References

    1. Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavin MA, Thursky KA; National Antimicrobial Prescribing Survey (NAPS) . Antimicrobial allergy “labels” drive inappropriate antimicrobial prescribing: lessons for stewardship. J Antimicrob Chemother 2016; 71:1715–22.
    1. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet 2019; 393:183–98.
    1. Blumenthal KG, Lu N, Zhang Y, Li Y, Walensky RP, Choi HK. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018; 361:k2400.
    1. Sousa-Pinto B, Cardoso-Fernandes A, Araujo L, Fonseca JA, Freitas A, Delgado L. Clinical and economic burden of hospitalizations with registration of penicillin allergy. Ann Allergy Asthma Immunol 2018; 120:190–4.e2.
    1. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol 2014; 133:790–6.
    1. Blumenthal KG, Lu N, Zhang Y, Walensky RP, Choi HK. Recorded penicillin allergy and risk of mortality: a population-based matched cohort study. J Gen Intern Med 2019; 34:1685–7.
    1. Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy is not necessarily forever. JAMA 2017; 318:82–3.
    1. Trubiano J, Phillips E. Antimicrobial stewardship’s new weapon? A review of antibiotic allergy and pathways to “de-labeling.” Curr Opin Infect Dis 2013; 26:526–37.
    1. Barlam TF, Cosgrove SE, Abbo LM, et al. . Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62:e51–77.
    1. Trubiano JA, Thursky KA, Stewardson AJ, et al. . Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis 2017; 65:166–74.
    1. Banks TA, Tucker M, Macy E. Evaluating penicillin allergies without skin testing. Curr Allergy Asthma Rep 2019; 19:27.
    1. Mustafa SS, Conn K, Ramsey A. Comparing direct challenge to penicillin skin testing for the outpatient evaluation of penicillin allergy: a randomized controlled trial. J Allergy Clin Immunol Pract 2019; 7:2163–70.
    1. Devchand M, Urbancic KF, Khumra S, et al. . Pathways to improved antibiotic allergy and antimicrobial stewardship practice: the validation of a beta-lactam antibiotic allergy assessment tool. J Allergy Clin Immunol Pract 2019; 7:1063–5.e5.
    1. Trubiano JA, Smibert O, Douglas A, et al. . The safety and efficacy of an oral penicillin challenge program in cancer patients: a multicenter pilot study. Open Forum Infect Dis 2018; 5:ofy306.
    1. Trubiano JA, Pai Mangalore R, Baey YW, et al. . Old but not forgotten: antibiotic allergies in general medicine (the AGM Study). Med J Aust 2016; 204:273.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.
    1. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods 2010; 15:15.
    1. Mill C, Primeau MN, Medoff E, et al. . Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children. JAMA Pediatr 2016; 170:e160033.
    1. Vezir E, Dibek Misirlioglu E, Civelek E, et al. . Direct oral provocation tests in non-immediate mild cutaneous reactions related to beta-lactam antibiotics. Pediatr Allergy Immunol 2016; 27:50–4.
    1. Confino-Cohen R, Rosman Y, Meir-Shafrir K, et al. . Oral challenge without skin testing safely excludes clinically significant delayed-onset penicillin hypersensitivity. J Allergy Clin Immunol Pract 2017; 5:669–75.
    1. Labrosse R, Paradis L, Lacombe-Barrios J, et al. . Efficacy and safety of 5-day challenge for the evaluation of nonsevere amoxicillin allergy in children. J Allergy Clin Immunol Pract 2018; 6:1673–80.
    1. Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. . Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing. J Allergy Clin Immunol Pract 2019; 7:236–43.
    1. du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. J Antimicrob Chemother 2019; 74:1438–46.
    1. Li J, Shahabi-Sirjani A, Figtree M, Hoyle P, Fernando SL. Safety of direct drug provocation testing in adults with penicillin allergy and association with health and economic benefits. Ann Allergy Asthma Immunol 2019; 123:468–75.
    1. Stevenson B, Trevenen M, Klinken E, et al. . Multicenter Australian study to determine criteria for low- and high-risk penicillin testing in outpatients. J Allergy Clin Immunol Pract 2020; 8:681–9.e3.
    1. Ibanez MD, Rodriguez Del Rio P, Lasa EM, et al. . Prospective assessment of diagnostic tests for pediatric penicillin allergy: from clinical history to challenge tests. Anna Allergy Asthma Immunol 2018; 121:235–44.e3.
    1. Tucker MH, Lomas CM, Ramchandar N, Waldram JD. Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J Allergy Clin Immunol Pract 2017; 5:813–5.
    1. Vyles D, Adams J, Chiu A, Simpson P, Nimmer M, Brousseau DC. Allergy testing in children with low-risk penicillin allergy symptoms. Pediatrics 2017; 140:e20170471.
    1. Mattingly TJ 2nd, Fulton A, Lumish RA, et al. . The cost of self-reported penicillin allergy: a systematic review. J Allergy Clin Immunol Pract 2018; 6:1649–54.e4.
    1. Trubiano J, Vogrin S, Holmes NE, et al. . Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med 2020; 180:1–9.

Source: PubMed

3
订阅